[Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis]
| Autor: | V V, Ptuskin, A L, Uss, E A, Demina, Iu V, Chervonobab, N F, Milanovich, N N, Tupitsyn, V B, Larionova, Z E, Batan, N E, Kondrat'eva, V A, Zmachinskiĭ, L A, Andreeva, V M, Snegir', D M, Mkheidze, K L, Chimishkian |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male Adolescent Remission Induction Cytarabine Hematopoietic Stem Cell Transplantation Prognosis Carmustine Combined Modality Therapy Hodgkin Disease Transplantation Autologous Disease-Free Survival Recurrence Antineoplastic Combined Chemotherapy Protocols Humans Female Radiotherapy Adjuvant Melphalan Etoposide |
| Zdroj: | Terapevticheskii arkhiv. 69(10) |
| ISSN: | 0040-3660 |
| Popis: | Eighteen patients with relapsed or refractory Hodgkin's disease (HD) have been treated with high-dose chemotherapy (BEAM regimen) followed by autologous peripheral stem cells and/or bone marrow rescue. There were no treatment-related deaths. Overall response rate was 82%. With a median follow-up of 10 months (3-24 months) overall survival and freedom from progression were 100 and 94% (95% confidence interval 58-97%), respectively. The use of peripheral stem cells in addition to bone marrow resulted in a significant shortening of the time to engraftment (p0.01). The BEAM regimen is an effective conditioning schedule which is well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|